Madrigal Pharmaceuticals, Inc. (MDGL) financial statements (2021 and earlier)

Company profile

Business Address 200 BARR HARBOR DRIVE, SUITE 400
WEST CONSHOHOCKEN, PA 19428
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments284336384409439454466
Cash and cash equivalents541096267478973
Short-term investments230227323342392364394
Other undisclosed current assets1221122
Total current assets:285338387409440455469
Noncurrent Assets
Operating lease, right-of-use asset111111 
Property, plant and equipment1111100
Other undisclosed noncurrent assets      1
Total noncurrent assets:2222211
TOTAL ASSETS:287340388411442456470
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities46494525251512
Accounts payable1651110
Accrued liabilities45434024241412
Debt   000 
Other undisclosed current liabilities000   0
Total current liabilities:47494526251512
Noncurrent Liabilities
Long-term debt and lease obligation010000 
Operating lease, liability010000 
Other undisclosed noncurrent liabilities (1)(0)   1
Total noncurrent liabilities:0100001
Total liabilities:47504526251613
Stockholders' equity
Stockholders' equity attributable to parent240290343385417440457
Common stock0000000
Additional paid in capital665656650644640636631
Accumulated other comprehensive income0010000
Accumulated deficit(425)(366)(308)(259)(223)(195)(174)
Total stockholders' equity:240290343385417440457
TOTAL LIABILITIES AND EQUITY:287340388411442456470

Income statement (P&L) ($ in millions)

12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
Gross profit:  0    
Operating expenses(60)(59)(50)(38)(30)(24)(23)
Other undisclosed operating loss  (0)    
Operating loss:(60)(59)(50)(38)(30)(24)(23)
Loss before gain (loss) on sale of properties:(60)(59)(50)(38)(30)(24)(23)
Other undisclosed net income0  22  
Net loss:(59)(59)(50)(36)(28)(24)(23)
Other undisclosed net income attributable to parent 11  33
Net loss available to common stockholders, diluted:(59)(58)(49)(36)(28)(21)(20)

Comprehensive Income ($ in millions)

12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
Net loss:(59)(59)(50)(36)(28)(24)(23)
Comprehensive loss:(59)(59)(50)(36)(28)(24)(23)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(0)020(0)33
Comprehensive loss, net of tax, attributable to parent:(59)(59)(48)(36)(28)(22)(19)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: